Table 2.
Mean Marker Levels by Treatment Groups Versus Cognitive Decline Status.
| Patient group | |||
|---|---|---|---|
| Serum marker status | No cognitive decline | Cognitive decline | P value* |
| SRS group | No CDat3, n = 25 | CDat3, n = 19 | |
| ApoE | 32.696 (9.986) | 24.305 (9.406) | .007 |
| Amyloid beta | 58.840 (17.927) | 69.916 (17.853) | .048 |
| ApoA1 | 150.644 (32.367) | 113.147 (23.257) | <.001 |
| ApoJ | 151.772 (30.032) | 111.411 (23.872) | <.001 |
| WBRT group | No CDat3; n = 3 | CDat3; n = 26 | |
| ApoE | 22.233 (12.626) | 19.811 (11.544) | .735 |
| Amyloid Beta | 59.867 (17.110) | 70.246 (18.547) | .364 |
| ApoA1 | 102.467 (7.557) | 110.535 (15.774) | .395 |
| ApoJ | 162.467 (30.266) | 118.938 (26.822) | .014 |
Values are mean pg/mL (SD) for ApoE and Amyloid beta, and mg/dL (SD) for ApoA and ApoJ.
For each marker, means and standard deviations were calculated separately for each treatment group for patients without cognitive decline (NoCDat3) versus with cognitive decline at 3 months (CDat3).
*Means were compared with unequal variance t tests within each marker.